About: Characteristics of COVID-19 Clinical Trials in China Based on the Registration Data on ChiCTR and ClinicalTrials.gov

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Characteristics of COVID-19 Clinical Trials in China Based on the Registration Data on ChiCTR and ClinicalTrials.gov Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Characteristics of COVID-19 Clinical Trials in China Based on the Registration Data on ChiCTR and ClinicalTrials.gov
Creator	Yang, Juan He, Yingchun Huang, Jihan Su, Qianmin
Source	Medline; PMC
abstract	OBJECTIVE: This study aimed to evaluate the fundamental characteristics of coronavirus disease (COVID-19) clinical trials registered in China. METHODS: COVID-19 clinical trials registered in China were analyzed from databases on ChiCTR and ClinicalTrials.gov. The study designs, samples, primary end points, and intervention measures were evaluated. RESULTS: In total, 262 intervention clinical trials were retrieved on March 10, 2020. Overall, 181 (69.1%) trials involved two groups, 200 (76.3%) trials were randomized parallel trials, 24 (9.2%) trials were double blind, and 60.3% of trials included ≤100 participants. Sixty (22.9%) trials considered symptom improvement as the primary endpoint and 43 (16.4%) trials considered the rate or time at which the subjects became virus-free as the primary endpoint. Of 262 intervention studies, chemical drugs and biological products were studied in 105 (40.1%) intervention studies, of which antiviral drugs accounted for 15.3% and malaria drugs accounted for 8.4% of the studies. Among all trials, 27.9% of the studies used traditional Chinese medicine (TCM), 10.3% used cell therapy, and 5.0% used plasma therapy. CONCLUSION: This study is the first snapshot of the landscape of COVID-19 clinical trials registered in China and provided the basic features of clinical trial designs for the treatment and prevention of COVID-19 to offer useful information to guide future clinical trials on COVID-19 in other countries.
has issue date	2020-05-29(xsd:dateTime)
bibo:doi	10.2147/dddt.s254354
bibo:pmid	32581514
has license	cc-by-nc
sha1sum (hex)	3b38954db269a01118909ffedba27d915e27a7e7
schema:url	https://doi.org/10.2147/dddt.s254354
resource representing a document's title	Characteristics of COVID-19 Clinical Trials in China Based on the Registration Data on ChiCTR and ClinicalTrials.gov
has PubMed Central identifier	PMC7266821
has PubMed identifier	32581514
schema:publication	Drug Des Devel Ther
resource representing a document's body	covid:3b38954db269a01118909ffedba27d915e27a7e7#body_text
is schema:about of	named entity 'time' named entity 'primary endpoint' named entity 'participants' named entity 'biological products' named entity 'Registration' named entity 'studies' named entity 'cell therapy' named entity 'malaria' named entity 'United States' named entity 'interquartile range' named entity 'ClinicalTrials.gov' named entity 'double blind' named entity 'plasma' named entity 'antiviral therapy' named entity 'underlying diseases' named entity 'SAS Institute' named entity 'public health emergency of international concern' named entity 'kidney failure' named entity 'ClinicalTrials.gov' named entity 'clinical trials' named entity 'remdesivir' named entity 'Western medicine' named entity 'COVID' named entity 'China' named entity 'TCM' named entity 'primary outcome measure' named entity 'US National Institutes of Health' named entity 'coronavirus disease' named entity 'double-blinded' named entity 'COVID-19' named entity 'clinical trials' named entity 'Iran' named entity 'COVID-19' named entity 'clinical trials' named entity 'sample size' named entity 'antiviral drugs' named entity 'China' named entity 'clinical trials' named entity 'clinical trials' named entity 'clinical trials' named entity 'clinical trials' named entity 'ClinicalTrials.gov' named entity 'RNA virus' named entity 'mortality rates' named entity 'clinical trials' named entity 'critical illness' named entity 'China' named entity 'Microsoft' named entity 'sample size' named entity 'cure rate' named entity 'ritonavir' named entity 'traditional Indian medicinal' named entity 'baloxavir marboxil' named entity 'clinical trials' named entity 'therapeutic approaches' named entity 'COVID-19' named entity 'COVID' named entity 'virus' named entity 'ritonavir' named entity '5.7%' named entity 'clinical trials' named entity 'antimalarial drugs' named entity 'clinical trials' named entity 'clinical trials' named entity 'Clinical trials' named entity 'cough' named entity 'clinical trials' named entity 'severe acute respiratory syndrome' named entity 'psychological intervention' named entity 'virus' named entity 'clinical trials' named entity 'ritonavir' named entity 'research ethics' named entity 'darunavir/cobicistat' named entity 'COVID-19' named entity 'critically ill patients' named entity 'COVID-19' named entity 'clinical trials'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software